Trial Profile
Excellence in Peripheral Arterial Disease Treatment of Superficial Femoral Artery Disease With Drug-eluting Stents (XL PAD SFA DES)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Vascular restenosis
- Focus Therapeutic Use
- Acronyms XLPAD DES SFA
- 21 Sep 2018 New trial record